

Appendix 1. Diagnostic Characteristics of Using a Risk Score Cut-Point of ≥ 20 to Identify Women at High Risk of Residual Urinary Incontinence Within 120 Days of Fistula Repair Surgery

	True Event	True non-Event	
Event identified by risk score	74	97	171
Non-event identified by risk score	17	166	183
	91	263	354

Sensitivity	$74/91 = 81\%$
Specificity	$166/263 = 63\%$
Positive predictive value	$74/171 = 43\%$
Negative predictive value	$166/183 = 91\%$

Proportion of the population identified by the risk score for intervention	$171/354 = 48\%$
Proportion of the population where the risk score incorrectly predicted event	$97/354 = 27\%$
Proportion of the population where the risk score missed predicting an event	$17/354 = 5\%$

Seidman D and Weber S. Integrating pre-exposure prophylaxis for human immunodeficiency virus prevention into women's health care in the United States. *Obstet Gynecol* 2016; 128.

The authors provided this information as a supplement to their article.

©2016 American College of Obstetricians and Gynecologists.

Appendix 2. Risk Score for Residual Urinary Incontinence Within 120 Days of Vesicovaginal Fistula Repair Surgery

Directions:

- All women start with a score of 0.
- Check off box correct category for each risk factor.
- Sum the points for all risk factors and record the final risk score at the bottom.

Risk Factor	Check correct box	Points
Age		
≤ 50	<input type="checkbox"/>	0
>50	<input type="checkbox"/>	17
Number of Prior Surgeries		
0	<input type="checkbox"/>	0
≥1	<input type="checkbox"/>	12
Goh VVF Size		
<1.5 cm	<input type="checkbox"/>	0
1.5 – 3.0 cm	<input type="checkbox"/>	8
> 3.0 cm	<input type="checkbox"/>	7
Circumferential Fistula		
No	<input type="checkbox"/>	0
Yes	<input type="checkbox"/>	15
Vaginal Scarring		
None or Mild	<input type="checkbox"/>	0
Moderate or Severe or Obliterated	<input type="checkbox"/>	7
Urethral Length		
> 1.5 cm	<input type="checkbox"/>	0
≤1.5 cm	<input type="checkbox"/>	6

Sum points for all checked boxes

RISK SCORE

Seidman D and Weber S. Integrating pre-exposure prophylaxis for human immunodeficiency virus prevention into women’s health care in the United States. *Obstet Gynecol* 2016; 128.

The authors provided this information as a supplement to their article.

©2016 American College of Obstetricians and Gynecologists.